For example, nBT062, a SDC-1-specific monoclonal antibody, could inhibit the growth of multiple myeloma cells without inducing cytotoxicity against normal peripheral blood mononuclear cells.65 Also, OC-46F2, an antibody specifically targeting the extracellular domain of SDC-1, could inhibit tumor growth in human melanoma and ovarian carcinoma models.66 Moreover, an iodine-131-labeled anti-SDC-1 antibody is proved to be beneficial for refractory multiple myeloma patients in a phase I/II radioimmunotherapy study.67 This evidence concerns the gene SDC1 and neoplasm.